Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
19 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/19/2983602/0/en/LB-Pharmaceuticals-Names-Heather-Turner-as-CEO-to-Lead-its-Development-of-Transformative-Advances-in-Schizophrenia-Treatment.html
01 Oct 2024
// Ludwig Burger REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/roche-targets-more-than-3-billion-annual-obesity-sales-2024-09-30/
29 Jul 2024
// MONEYCONTROL
https://www.moneycontrol.com/news/world/roche-to-fast-track-weight-loss-drugs-to-compete-with-rivals-12780802.html
29 Jul 2024
// CONTRACT PHARMA
https://www.contractpharma.com/contents/view_breaking-news/2024-07-29/roche-completes-27b-acquisition-of-carmot-therapeutics/9769
29 Jul 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/07/29/2920445/0/en/Zealand-Pharma-Appoints-Eric-Cox-as-Chief-Commercial-Officer.html
17 Jul 2024
// PRESS RELEASE
Details:
Roche will enhance its portfolio with Carmot’s GLP-1/GIP receptor agonists, including CT-388, CT-996, and CT-868, for metabolic diseases like obesity and diabetes.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Brand Name: CT-388
Study Phase: Phase IProduct Type: Peptide
Sponsor: F. Hoffmann-La Roche
Deal Size: $3,100.0 million Upfront Cash: $2,700.0 million
Deal Type: Acquisition January 29, 2024
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $3,100.0 million
Deal Type : Acquisition
Carmot Therapeutics Announces Completion of Acquisition by Roche
Details : Roche will enhance its portfolio with Carmot’s GLP-1/GIP receptor agonists, including CT-388, CT-996, and CT-868, for metabolic diseases like obesity and diabetes.
Brand Name : CT-388
Molecule Type : Peptide
Upfront Cash : $2,700.0 million
January 29, 2024
Details:
Through the acquisition, Roche will build its portfolio by adding Carmot’s pipeline of GLP-1/GIP receptor agonist, including CT-388, CT-996 and CT-868 which are being evaluated for the treatment of metabolic diseases including obesity and diabetes.
Lead Product(s): CT-388
Therapeutic Area: Nutrition and Weight Loss Brand Name: CT-388
Study Phase: Phase IProduct Type: Peptide
Sponsor: F. Hoffmann-La Roche
Deal Size: $3,100.0 million Upfront Cash: $2,700.0 million
Deal Type: Acquisition December 04, 2023
Lead Product(s) : CT-388
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : $3,100.0 million
Deal Type : Acquisition
Carmot Therapeutics Enters into Definitive Merger Agreement with Roche
Details : Through the acquisition, Roche will build its portfolio by adding Carmot’s pipeline of GLP-1/GIP receptor agonist, including CT-388, CT-996 and CT-868 which are being evaluated for the treatment of metabolic diseases including obesity and diabetes.
Brand Name : CT-388
Molecule Type : Peptide
Upfront Cash : $2,700.0 million
December 04, 2023
Details:
The net proceeds will be used to advance the clinical development of CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, for the treatment of type-2 diabetes and obesity.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Brand Name: CT-388
Study Phase: Phase I/ Phase IIProduct Type: Peptide
Sponsor: J.P. Morgan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering November 17, 2023
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : Undisclosed
Deal Type : Public Offering
Obesity and Diabetes Biotech Carmot Therapeutics Files for IPO
Details : The net proceeds will be used to advance the clinical development of CT-388, a novel once-weekly dual GLP-1 and GIP receptor modulator, for the treatment of type-2 diabetes and obesity.
Brand Name : CT-388
Molecule Type : Peptide
Upfront Cash : Undisclosed
November 17, 2023
Details:
CT-868 is a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed as an adjunct to insulin for the treatment of people with type 1 diabetes (T1D) with overweight or obesity.
Lead Product(s): CT-868
Therapeutic Area: Endocrinology Brand Name: CT-868
Study Phase: Phase IIProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2023
Lead Product(s) : CT-868
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CT-868 is a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed as an adjunct to insulin for the treatment of people with type 1 diabetes (T1D) with overweight or obesity.
Brand Name : CT-868
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 15, 2023
Details:
CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). it was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP.
Lead Product(s): CT-996
Therapeutic Area: Endocrinology Brand Name: CT-996
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
Lead Product(s) : CT-996
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CT-996 is a once-daily oral, small molecule GLP-1 receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). it was designed to exhibit signaling bias on the GLP-1 receptor, resulting in activation of cAMP.
Brand Name : CT-996
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 10, 2023
Details:
The proceeds will be used to strengthen Carmot's portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis, including CT-388, a dual GLP-1/GIP receptor modulator for obese adults with and without type 2 diabetes.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Brand Name: CT-388
Study Phase: Phase IProduct Type: Peptide
Sponsor: Deep Track Capital
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing May 25, 2023
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Deep Track Capital
Deal Size : $150.0 million
Deal Type : Series E Financing
Details : The proceeds will be used to strengthen Carmot's portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis, including CT-388, a dual GLP-1/GIP receptor modulator for obese adults with and withou...
Brand Name : CT-388
Molecule Type : Peptide
Upfront Cash : Undisclosed
May 25, 2023
Details:
The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Brand Name: CT-388
Study Phase: Phase IProduct Type: Peptide
Recipient: Kimia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Demerger January 05, 2023
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Recipient : Kimia Therapeutics
Deal Size : Undisclosed
Deal Type : Demerger
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease
Details : The spin-off enables Carmot to focus on clinical-stage candidates CT-388 and CT-868 (dual GLP-1/GIP receptor modulators), additional IND-stage programs including CT-996 (an oral, small molecule GLP-1 receptor agonist) and a long-acting PYY analogue.
Brand Name : CT-388
Molecule Type : Peptide
Upfront Cash : Undisclosed
January 05, 2023
Details:
The funding will support the phase 2 studies for CT-388, a dual modulator of the GLP-1 and GIP incretin receptors, phase 1 studies for CT-996, an oral small molecule GLP-1 receptor agonist, and phase 2 studies for CT-868, a first-inclass fully biased GLP-1/GIP modulator.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Brand Name: CT-388
Study Phase: Phase IProduct Type: Peptide
Sponsor: The Column Group
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 26, 2022
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : The Column Group
Deal Size : $160.0 million
Deal Type : Series D Financing
Details : The funding will support the phase 2 studies for CT-388, a dual modulator of the GLP-1 and GIP incretin receptors, phase 1 studies for CT-996, an oral small molecule GLP-1 receptor agonist, and phase 2 studies for CT-868, a first-inclass fully biased GLP...
Brand Name : CT-388
Molecule Type : Peptide
Upfront Cash : Undisclosed
July 26, 2022
Details:
FDA recently approved LUMAKRAS for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Lead Product(s): Sotorasib
Therapeutic Area: Oncology Brand Name: Lumakras
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Amgen Inc
Deal Size: $240.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration June 29, 2021
Carmot to Receive Royalty Payments Upon Sales of Amgen’s FDA Approved First-in-class KRAS G12C I...
Details : FDA recently approved LUMAKRAS for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Brand Name : Lumakras
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 29, 2021
Details:
CT-388 is a fully biased dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor, anticipated to be dosed once-weekly.
Lead Product(s): CT-388
Therapeutic Area: Endocrinology Brand Name: CT-388
Study Phase: Phase IProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Lead Product(s) : CT-388
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CT-388 is a fully biased dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor, anticipated to be dosed once-weekly.
Brand Name : CT-388
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 24, 2021
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?